SWOG-LED:


S0777 Brian Durie, Shaji Kumar, Eric Ammann, Alex Fu, Shuchita Kaila, Annette Lam, Saad Usmani, Thierry Facon. Adjusted indirect treatment comparison of progression-free survival (PFS) associated with DRd and VRd based on MAIA and SWOG S0777 individual patient-level data. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session, 2023. https://meetings.asco.org/abstracts-presentations/226705


 orteronel (cyp17 inhibitor) or bicalutamide. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session, 2023. 
https://meetings.asco.org/abstracts-presentations/218390


circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) (SWOG S1802). ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session, 2023. https://meetings.asco.org/abstracts-presentations/222758


S2001 Chung V, Guthrie K, Pishvaian M, Reiss K, Lowy A, Sohal D, Colby S, Sharon E, Allegra C, O'Reilly E, Chiorean E, Philip P. Randomized Phase II Trial of Olaparib + Pembrolizumab vs Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 (gBRCA1/2+) Mutations: SWOG S2001 NCT04548752. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), TIP poster session, 2023. https://meetings.asco.org/abstracts-presentations/226078


Enrolled on Clinical Trials. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), publication only, 2023. https://meetings.asco.org/abstracts-presentations/219424

MULTIPLE Joseph Unger, Caroline Schenkel, Hillary Stires, Laura Levit, Mark Stewart, Brittany McKelvey, Beverly Canin, Emily Dressler, Keith Flaherty, Peter Fredette, Lee Jones, Margaret McCann, Therica Miller, Adedayo Onitilo, Frances Palmieri, Timil Patel, Rocio Paul, Gary Smith, Suanna Bruinooge, Ajjai Alva. Impact of COVID-19 pandemic mitigation strategies on industry and NCI cancer treatment trials. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), accepted, poster session, 2023. https://meetings.asco.org/abstracts-presentations/219437


OTHER GROUP-LED:

Pheochromocytoma and Paraganglioma. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), accepted, poster session, 2023. https://meetings.asco.org/abstracts-presentations/225867


MULTIPLE        Susan Halabi, Siyuan Guo, Akash Roy, Larysa Rydzewska, Peter Godolphin, Maha Hussain, Catherine Tangen, Ian Thompson, Wanling Xie, Michael Carducci, Matthew Smith, Michael Morris, Gwenaelle Gravis, David Dearnaley, Paul Verhagen, Takayuki Goto, Nicholas James, Mahesh Parmar, Marc Buyse, Christopher Sweeney. The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC). ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), accepted, poster session, 2023. https://meetings.asco.org/abstracts-presentations/222722

MULTIPLE        Susan Halabi, Akash Roy, Siyuan Guo, Larysa Rydzewska, Peter Godolphin, Maha Hussain, Catherine Tangen, Ian Thompson, Wanling Xie, Michael Carducci, Matthew Smith, Michael Morris, Gwenaelle Gravis, David Dearnaley, Paul Verhagen, Takayuki Goto, Jayne Tierney, Nicholas James, Marc Buyse, Christopher Sweeney. Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic
hormone-sensitive prostate cancer (mHSPC). ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), accepted, poster session, 2023.
https://meetings.asco.org/abstracts-presentations/222713